Help Fund an Early-Career Researcher
Eighty-eight cents of every dollar you give does directly to cancer research. Cancer Research Saves Lives.
Related Articles
Optimizing Treatment Sequences Remains Key in CLL/SLL
Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.
Treatment Sequencing Strategies in R/R Multiple Myeloma
A panel of experts on multiple myeloma review patient cases and discuss the treatment of patients with relapsed/refractory disease, highlighting sequencing strategies and clinical trials…
Paying It Forward: The Importance of Mentorship in a Medical Career
Beyond a lengthy list of accomplishments across the leukemia spectrum of treatment, Garcia-Manero holds the importance of mentorship as incredibly dear to his heart and…
Become a Member Today
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,900 physicians, investigators and other health care professionals…
3 QUESTIONS ON . . . The Impact of Historical Redlining on… : Oncology Times
An abstract is unavailable.
Preparation is Key to Tackle the Transition from Fellow to Attending Physician
A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.
Phase II trial results on enzalutamide and paclitaxel in LAR-enriched TNBC
Bora Lim, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides a brief overview on the Phase II trial (NCT02276443) of neoadjuvant…
Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia
Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.
Dr Buchbinder on the Potential Role for RP1 Plus Nivolumab in Melanoma After PD-1 Progression
Elizabeth Buchbinder, MD, discusses the implications of the FDA’s decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.
Dr Garmezy on the Rationale for Developing Zelenectide Pevedotin in Urothelial Cancer
Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.